The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia
Launched by UNIVERSITY OF PITTSBURGH · Aug 30, 2001
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • Hemophilia.
- • HIV-seropositivity confirmed by Western Blot.
- Prior Medication:
- Required:
- • - AZT for study patients.
- Allowed:
- • - Ibuprofen.
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following symptoms and conditions are excluded:
- • Hospitalization for opportunistic infection, bacterial infection or malignancy.
- Concurrent Medication:
- Excluded:
- • AZT (for control group).
- • Antibiotics or other medication for opportunistic infection, bacterial infection, or malignancy.
- Patients with the following prior conditions are excluded:
- • Hospitalization for opportunistic infection, bacterial infection, or malignancy.
- Required:
- • Ibuprofen.
- • AZT 1-2 gm daily (for study patient) or not taking AZT (for control).
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials